版本:
中国

BRIEF-Syros announces first patient dosed in phase 1 clinical trial of SY-1365

May 15 Syros Pharmaceuticals Inc

* Syros announces first patient dosed in phase 1 clinical trial of SY-1365, its first-in-class selective CDK7 inhibitor, in patients with advanced solid tumors Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐